Figures & data
Table 1. Baseline characteristics of included patients.
Figure 1. Comparison of ΔeGFR [0 to 6] and ΔeGFR [6 to 12] with ΔeGFR [−6 to 0] in patients with eGFR <75 mL/min/1.73m2.The values of ΔeGFR [−6 to 0], ΔeGFR [0 to 6], and ΔeGFR [6 to 12] were −1.0, +1.8, and 0.0, respectively. Pirfenidone significantly suppressed renal function decline for up to 6 months after starting treatment (p = .010).
![Figure 1. Comparison of ΔeGFR [0 to 6] and ΔeGFR [6 to 12] with ΔeGFR [−6 to 0] in patients with eGFR <75 mL/min/1.73m2.The values of ΔeGFR [−6 to 0], ΔeGFR [0 to 6], and ΔeGFR [6 to 12] were −1.0, +1.8, and 0.0, respectively. Pirfenidone significantly suppressed renal function decline for up to 6 months after starting treatment (p = .010).](/cms/asset/ec518d89-5009-456a-9346-3b3b413c9587/irnf_a_1925297_f0001_b.jpg)
Figure 2. Comparison of ΔeGFR [0 to 6] and ΔeGFR [6 to 12] with ΔeGFR [−6 to 0] in patients with eGFR <60 mL/min/1.73m2.The values of ΔeGFR [−6 to 0], ΔeGFR [0 to 6], and ΔeGFR [6 to 12] were −2.5, +1.6, and −0.7, respectively. Compared to baseline values, pirfenidone significantly suppressed the renal function decline up to 6 months after starting treatment (p < .001), additionally showing tendency to suppress renal function even at 12 months after treatment (p = .136).
![Figure 2. Comparison of ΔeGFR [0 to 6] and ΔeGFR [6 to 12] with ΔeGFR [−6 to 0] in patients with eGFR <60 mL/min/1.73m2.The values of ΔeGFR [−6 to 0], ΔeGFR [0 to 6], and ΔeGFR [6 to 12] were −2.5, +1.6, and −0.7, respectively. Compared to baseline values, pirfenidone significantly suppressed the renal function decline up to 6 months after starting treatment (p < .001), additionally showing tendency to suppress renal function even at 12 months after treatment (p = .136).](/cms/asset/fda1fc05-e0b5-425e-bb83-1af57c3535ba/irnf_a_1925297_f0002_b.jpg)